The Ligandable Human Proteome

Bile acid receptor

Nuclear hormone receptor, ligand-binding domain

Index	Ligand Name	Structure	PDB code	Compound Potency nM
1	ook	Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3,5-difluorobenzoic acid	3ook	4
2	9l1	Ligand binding to FARNESOID-X-RECEPTOR	5q0m	7.9
3	9na	Ligand binding to FARNESOID-X-RECEPTOR	5q1c	8.4
4	9l4	Ligand binding to FARNESOID-X-RECEPTOR	5q0n	8.7
5	9mp	Ligand binding to FARNESOID-X-RECEPTOR	5q15	8.9
6	9n4	Ligand binding to FARNESOID-X-RECEPTOR	5q1a	9.6
7	9ms	Ligand binding to FARNESOID-X-RECEPTOR	5q16	13.5
8	olf	Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3-methylbenzoic acid	3olf	20
9	9ls	Ligand binding to FARNESOID-X-RECEPTOR	5q0v	20.5
10	9mm	Ligand binding to FARNESOID-X-RECEPTOR	5q14	21
11	9l7	Ligand binding to FARNESOID-X-RECEPTOR	5q0o	24.4
12	omm	Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3-fluorobenzoic acid	3omm	37
13	9la	Ligand binding to FARNESOID-X-RECEPTOR	5q0p	39
14	643	Ligand binding to FARNESOID-X-RECEPTOR	5q0x	45
15	9n1	Ligand binding to FARNESOID-X-RECEPTOR	5q19	48
16	9n7	Ligand binding to FARNESOID-X-RECEPTOR	5q1b	48.7
17	oof	Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)benzoic acid	3oof	50
18	9lv	Ligand binding to FARNESOID-X-RECEPTOR	5q0w	58
19	9lj	Ligand binding to FARNESOID-X-RECEPTOR	5q0s	62
20	9my	Ligand binding to FARNESOID-X-RECEPTOR	5q18	67.5
21	oki	Crystal structure of human FXR in complex with (2S)-2-[2-(4-chlorophenyl)-1H-benzimidazol-1-yl]-N,2-dicyclohexylethanamide	3oki	70
22	9nj	Ligand binding to FARNESOID-X-RECEPTOR	5q1f	72.5
23	9md	Ligand binding to FARNESOID-X-RECEPTOR	5q13	91
24	643	Identification of an N-oxide pyridine GW4064 analogue as a potent FXR agonist	3fxv	94
25	064	FXR with SRC1 and GW4064	3dct	112
26	9ng	Ligand binding to FARNESOID-X-RECEPTOR	5q1e	120
27	9lp	Ligand binding to FARNESOID-X-RECEPTOR	5q0u	175
28	9kv	Ligand binding to FARNESOID-X-RECEPTOR	5q0j	239
29	9o1	Ligand binding to FARNESOID-X-RECEPTOR	5q1i	570
30	9nd	Ligand binding to FARNESOID-X-RECEPTOR	5q1d	760
31	9ld	Ligand binding to FARNESOID-X-RECEPTOR	5q0q	785
32	9ly	Ligand binding to FARNESOID-X-RECEPTOR	5q0y	1870
33	9ky	Ligand binding to FARNESOID-X-RECEPTOR	5q0l	4360
34	9ma	Ligand binding to FARNESOID-X-RECEPTOR	5q12	4640
35	9mv	Ligand binding to FARNESOID-X-RECEPTOR	5q17	5640
36	okh	Crystal structure of human FXR in complex with 2-(4-chlorophenyl)-1-[(1S)-1-cyclohexyl-2-(cyclohexylamino)-2-oxoethyl]-1H-benzimidazole-6-carboxylic acid	3okh	5720
37	9m4	Ligand binding to FARNESOID-X-RECEPTOR	5q10	6280
38	9m7	Ligand binding to FARNESOID-X-RECEPTOR	5q11	7190
39	9np	Ligand binding to FARNESOID-X-RECEPTOR	5q1h	7950
40	xx9	Structural basis for small molecule NDB as a selective antagonist of FXR	4oiv	8290
41	9lg	Ligand binding to FARNESOID-X-RECEPTOR	5q0r	2.7e+004
42	9lm	Ligand binding to FARNESOID-X-RECEPTOR	5q0t	2.9e+004
43	9nm	Ligand binding to FARNESOID-X-RECEPTOR	5q1g	2.63e+005